General Proximity is a San Francisco-based biotech startup founded in 2019. The company focuses on developing "proximity medicines" to treat diseases by targeting proteins previously considered untreatable, such as those involved in cancer, neurodegeneration, cardiometabolic disorders, and aging-related conditions. Using their OmniTAC platform, they manipulate "effector proteins" to precisely control disease-related protein behaviors like degradation, refolding, and localization.

General Proximity has raised $16 million from investors, including Felicis, Y Combinator, and Healthspan Capital, and secured grants like a $3 million ARPA-H award for women’s cancer therapeutics. Their team includes top scientists from institutions like Harvard, Oxford, and MIT, as well as pharmaceutical veterans from major companies like Novartis and Merck. They aim to revolutionize drug discovery and extend human healthspan through innovative proximity-based approaches.